NC_000002.11:g.(?_232952187)_(233201340_?)del AND Perlman syndrome

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Dec 17, 2021
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003113696.2

Allele description

NC_000002.11:g.(?_232952187)_(233201340_?)del

Gene:
DIS3L2:DIS3 like 3'-5' exoribonuclease 2 [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
2q37.1
Genomic location:
Chr2: 232952187 - 233201340 (on Assembly GRCh37)
Preferred name:
NC_000002.11:g.(?_232952187)_(233201340_?)del
HGVS:
NC_000002.11:g.(?_232952187)_(233201340_?)del

Condition(s)

Name:
Perlman syndrome (PRLMNS)
Synonyms:
Renal hamartomas nephroblastomatosis and fetal gigantism; Nephroblastomatosis fetal ascites macrosomia and wilms tumor
Identifiers:
MONDO: MONDO:0009965; MedGen: C0796113; Orphanet: 2849; OMIM: 267000

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV003796775Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Dec 17, 2021)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility.

Astuti D, Morris MR, Cooper WN, Staals RH, Wake NC, Fews GA, Gill H, Gentle D, Shuib S, Ricketts CJ, Cole T, van Essen AJ, van Lingen RA, Neri G, Opitz JM, Rump P, Stolte-Dijkstra I, Müller F, Pruijn GJ, Latif F, Maher ER.

Nat Genet. 2012 Feb 5;44(3):277-84. doi: 10.1038/ng.1071.

PubMed [citation]
PMID:
22306653

Homozygous deletion of DIS3L2 exon 9 due to non-allelic homologous recombination between LINE-1s in a Japanese patient with Perlman syndrome.

Higashimoto K, Maeda T, Okada J, Ohtsuka Y, Sasaki K, Hirose A, Nomiyama M, Takayanagi T, Fukuzawa R, Yatsuki H, Koide K, Nishioka K, Joh K, Watanabe Y, Yoshiura K, Soejima H.

Eur J Hum Genet. 2013 Nov;21(11):1316-9. doi: 10.1038/ejhg.2013.45. Epub 2013 Mar 13.

PubMed [citation]
PMID:
23486540
PMCID:
PMC3798850
See all PubMed Citations (3)

Details of each submission

From Invitae, SCV003796775.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (3)

Description

This variant is a gross deletion of the genomic region encompassing exon(s) 6-21 of the DIS3L2 gene, which includes the termination codon. This deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. While this deletion is not anticipated to lead to nonsense mediated decay, it is expected to alter mRNA translation or result in a truncated protein product. This variant has not been reported in the literature in individuals affected with DIS3L2-related conditions. This variant disrupts a region of the DIS3L2 protein in which other variant(s) (deletion of exon 9) have been determined to be pathogenic (PMID: 22306653, 23486540). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Feb 18, 2023